文献速递神经肌肉病

不同呼吸测试参数在检测肌萎缩侧索硬化患者早期呼吸功能不全中的性能比较

Comparative Performance of Different Respiratory Test Parameters for Detection of Early Respiratory Insufficiency in Patients With ALS.
PubMed 文献 · Neurology · 2022-05-18

该研究比较了多学科ALS门诊中不同呼吸功能测试参数的性能。研究发现,夜间脉搏血氧测定和最大吸气压异常较用力肺活量更早出现,且出现异常后中位生存期更短;93.1%患者符合Medicare无创通气标准,但使用率不足50%。作者认为夜间血氧和最大吸气压在早期检测神经肌肉呼吸无力方面优于用力肺活量。

要点

  • 夜间血氧和最大吸气压异常出现时间早于用力肺活量(中位1.6年和1.5年 vs 3.8年)。
  • 出现呼吸症状时,夜间血氧异常占60%,最大吸气压异常占69%,用力肺活量异常仅19%。
  • 93.1%患者符合Medicare无创通气标准,但使用率不足50%。

核心结论

  • 夜间脉搏血氧测定和最大吸气压异常在早期检测ALS神经肌肉呼吸无力方面优于用力肺活量。
  • 对呼吸功能不全的ALS患者启动无创通气可能改善总体生存。

研究设计与样本

  • 回顾性队列研究,纳入2008年至2016年多学科ALS门诊的476例至少接受1次呼吸测试的患者。

主要发现

  • 从发病至出现夜间血氧、最大吸气压和用力肺活量异常的中位时间分别为1.6年、1.5年和3.8年(p < 0.00001)。
  • 延髓起病ALS患者最大吸气压和用力肺活量异常早于脊髓起病者(p < 0.005)。
  • 出现夜间血氧、最大吸气压或用力肺活量异常后的中位生存期分别为1.4年、1.4年和0.9年(p < 0.0001)。
  • 443例患者(93.1%)出现至少1项符合Medicare无创通气标准的呼吸指标异常,但队列中无创通气使用率不足50%。
  • 使用无创通气的延髓起病ALS患者生存改善具有统计学显著性。

关键数值与推荐

  • Medicare启动无创通气的标准:用力肺活量<50%预计值、最大吸气压<60 cm H2O或夜间脉搏血氧测定异常。

临床怎么用

  • 在COVID-19大流行背景下,因产生感染性气溶胶,用力肺活量和最大吸气压未常规进行。
  • 本研究中心目前常规将夜间脉搏血氧仪邮寄至患者家中,并在COVID-19大流行期间独家使用,以实现对ALS患者呼吸状态的持续远程监测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: To compare the performance of different respiratory function testing parameters in a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic. METHODS: Demographics, clinical data, and respiratory testing parameters were abstracted from the medical records of patients who attended a multidisciplinary ALS clinic from 2008 to 2016. We compared the performance of the 3 primary respiratory test parameters used by Medicare for the initiation of noninvasive ventilation (NIV) (forced vital capacity [FVC] < 50% predicted, maximum inspiratory pressure [MIP] < 60 cm H2O, and abnormal overnight pulse oximetry [OvOx]) on how they related to several clinically relevant attributes. RESULTS: Four hundred seventy-six patients were identified who underwent at least 1 respiratory test. Abnormalities of OvOx, MIP, and FVC occurred at a median of 1.6, 1.5, and 3.8 years from disease onset, respectively (p < 0.00001). Patients with bulbar-onset ALS exhibited earlier abnormalities in MIP and FVC than in spinal-onset ALS (p < 0.005). The median survival after an abnormal OvOx, MIP, or FVC test was 1.4, 1.4, and 0.9 years, respectively (p < 0.0001). Using the ALS Functional Rating Score respiratory subscales, at the time of reported respiratory symptoms there were abnormalities in OvOx (60%), MIP (69%), and FVC (19%). Conversely, when respiratory parameter abnormalities preceded reported respiratory symptoms, this occurred with frequencies in OvOx (79%), MIP (42%), or FVC (24%). Four hundred forty-three patients (93.1%) developed at least 1 abnormal respiratory measure meeting Medicare criteria for NIV consideration, but fewer than 50% in our cohort demonstrated NIV use. Improved survival in subjects using NIV was statistically significant in patients with bulbar-onset ALS. DISCUSSION: Abnormalities in OvOx and MIP perform better than FVC at early detection of neuromuscular respiratory weakness in ALS. Initiation of NIV in patients with respiratory insufficiency may improve the overall survival in ALS. In the setting of the COVID-19 pandemic, FVC and MIP have not been routinely performed because of infectious aerosol generation. OvOx, which we now routinely mail to patients' homes, has been used exclusively during the COVID-19 pandemic and allows for continued remote monitoring of the respiratory status of patients with ALS. CLASSIFICATION OF EVIDENCE: This cohort study provides Class III evidence that in people with ALS, OvOx and MIP are valuable respiratory parameters for the detection of early respiratory insufficiency.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Kelly CR, Parra-Cantu C, Thapa P, et al. Comparative Performance of Different Respiratory Test Parameters for Detection of Early Respiratory Insufficiency in Patients With ALS. Neurology. 2022. PMID: 35584920. doi:10.1212/WNL.0000000000200758

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。